利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

71 条记录 (耗时 0.042 秒)

    Peptide ligands of the urokinase receptor
    1.
    发明授权
    Peptide ligands of the urokinase receptor 失效

    公开(公告)号：US06794358B1

    公开(公告)日：2004-09-21

    申请号：US09155260

    申请日：1998-09-23

    申请人： Steven Rosenberg ,  Michael V. Doyle ,  Harold A. Chapman

    发明人： Steven Rosenberg ,  Michael V. Doyle ,  Harold A. Chapman

    IPC分类号： A61K3804

    CPC分类号： C07K7/06 ,  A61K38/00 ,  C07K7/08

    摘要： Novel peptides that are capable of binding to uPAR and inhibiting the binding of an integrin and vitronectin are described. Also provided are nucleic acid sequences encoding the novel peptides. Methods for screening for small molecules, other peptides, or peptoids that mimic the antagonistic function of the peptides of the invention are described. The invention has applications in design of therapeutics for treating disorders characterized by upregulation of uPA and uPAR, and cancer and chronic inflammation, cell migration or uPAR: integrin binding interactions, and diagnostical applications to such disorders.

    Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
    2.
    发明授权
    Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins 失效
    糖基化抗性的花青素和相关的缀合物，组合物，核酸，载体，宿主细胞，生产方法和使用非糖基化花青素的方法

    公开(公告)号：US06780847B2

    公开(公告)日：2004-08-24

    申请号：US09815079

    申请日：2001-03-22

    申请人： Michael R. Boyd

    发明人： Michael R. Boyd

    IPC分类号： A61K3804

    CPC分类号： A61K38/164 ,  A61K47/645 ,  A61K47/6817 ,  A61K47/6833 ,  A61L2/0082 ,  A61L2/0088 ,  A61L2/18 ,  A61L2/186 ,  A61L2/23 ,  C07K14/195

    摘要： An isolated and purified nucleic acid molecule that encodes a protein or peptide comprising at least nine contiguous amino acids of SEQ ID NO:2, wherein the at least nine contiguous amino acids comprise amino acids 30-32 of SEQ ID NO: 2 which have been rendered glycosylation resistant and wherein the at least nine contiguous amino acids have antiviral activity, a vector comprising such an isolated and purified nucleic acid molecule, a host cell or organism comprising the vector, a method of producing an antiviral protein or antiviral peptide, the antiviral protein or antiviral peptide itself, a conjugate comprising the antiviral protein or antiviral peptide, and compositions comprising an effective amount of the antiviral protein, antiviral peptide, antiviral protein conjugate or antiviral peptide conjugate. Further provided is a method of inhibiting prophylactically or therapeutically a viral infection, specifically an influenza viral infection, of a host.

    摘要翻译： 编码包含SEQ ID NO：2的至少九个连续氨基酸的蛋白质或肽的分离和纯化的核酸分子，其中所述至少九个连续氨基酸包含已经被SEQ ID NO：2的氨基酸30-32 提供的糖基化抗性并且其中所述至少九个连续氨基酸具有抗病毒活性，包含这种分离和纯化的核酸分子的载体，包含载体的宿主细胞或生物体，产生抗病毒蛋白或抗病毒肽的方法，抗病毒 蛋白质或抗病毒肽本身，包含抗病毒蛋白或抗病毒肽的缀合物，以及包含有效量的抗病毒蛋白，抗病毒肽，抗病毒蛋白缀合物或抗病毒肽缀合物的组合物。 进一步提供的是预防或治疗宿主的病毒感染，特别是流感病毒感染的方法。

    HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV
    3.
    发明授权
    HIV peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by HIV 有权
    HIV肽，抗原，疫苗组合物，免疫测定试剂盒和检测HIV诱导的抗体的方法

    公开(公告)号：US06706859B1

    公开(公告)日：2004-03-16

    申请号：US09674674

    申请日：2000-11-03

    申请人： Birger Sörensen

    发明人： Birger Sörensen

    IPC分类号： A61K3804

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/55522 ,  C12N2740/16222 ,  C12Q1/703

    摘要： The present invention comprises novel and modified peptides capable of inducing an HIV-1 specific immune response without antagonizing the cytotoxic T-cell activity in order to achieve an effective prophylactic and therapeutic vaccine against HIV. The peptides are based on conserved regions of HIV gag p24 proteins. Antigens in free- or carrier-bound form comprising at least one of the said peptides, vaccine compositions containing at least one of the antigens, immunoassay kits and a method of detecting antibodies induced by HIV or HIV specific peptides using such antigens, are described.

    摘要翻译： 本发明包括能够诱导HIV-1特异性免疫应答而不拮抗细胞毒性T细胞活性的新型和修饰的肽，以实现针对HIV的有效预防和治疗性疫苗。 肽基于HIV gag p24蛋白的保守区域。 描述了包含至少一种所述肽的疫苗，含有至少一种抗原的疫苗组合物，免疫测定试剂盒以及使用这种抗原检测由HIV或HIV特异性肽诱导的抗体的方法。

    NY-ESO-1 peptide derivatives, and uses thereof
    4.
    发明授权
    NY-ESO-1 peptide derivatives, and uses thereof 有权
    NY-ESO-1肽衍生物及其用途

    公开(公告)号：US06689742B1

    公开(公告)日：2004-02-10

    申请号：US09514036

    申请日：2000-02-25

    申请人： Vincenzo Cerundolo ,  Rodney Dunbar ,  Ji-li Chen

    发明人： Vincenzo Cerundolo ,  Rodney Dunbar ,  Ji-li Chen

    IPC分类号： A61K3804

    CPC分类号： C07K14/4748 ,  A61K39/00

    摘要： The invention relates to variant peptides which bind to HLA molecules, leading to lysis of cells via cytolytic T cell lines. The variants are based upon NY-ESO-1 peptides. The peptides can be incorporated into immune tetramers, which are useful as T cell sorters.

    摘要翻译： 本发明涉及与HLA分子结合的变体肽，导致通过溶细胞T细胞系裂解细胞。 这些变体基于NY-ESO-1肽。 这些肽可以并入免疫四聚体，其可用作T细胞分选机。

    Peptide compositions for the treatment of HIV infection
    5.
    发明授权
    Peptide compositions for the treatment of HIV infection 失效
    用于治疗HIV感染的肽组合物

    公开(公告)号：US06447778B1

    公开(公告)日：2002-09-10

    申请号：US09599286

    申请日：2000-06-22

    申请人： Arye Rubinstein ,  Barry R. Bloom ,  Yair Devash ,  Stanley J. Cryz

    发明人： Arye Rubinstein ,  Barry R. Bloom ,  Yair Devash ,  Stanley J. Cryz

    IPC分类号： A61K3804

    CPC分类号： C07K14/005 ,  A61K39/12 ,  A61K39/21 ,  A61K2039/54 ,  A61K2039/545 ,  A61K2039/57 ,  A61K2039/6037 ,  A61K2039/6068 ,  A61K2039/6081 ,  A61K2039/70 ,  C07K14/21 ,  C07K14/33 ,  C07K14/35 ,  C07K16/1063 ,  C07K16/1072 ,  C12N2740/16122 ,  C12N2740/16134 ,  C12N2740/16322 ,  C12N2740/16334

    摘要： The present invention provides for peptide conjugate compositions, methods of using the peptide conjugate compositions, and pharmaceutical compositions comprising the peptide conjugate compositions. The peptide conjugate compositions comprise peptides with amino acid sequences similar to the gp120 principal neutralizing domain (PND) of HIV, gp41, and Nef (p27) of HIV and carriers which enhance immunogenicity. The peptide conjugate compositions of the present invention may comprise a multivalent cocktail of several different peptide conjugates. Also provided by present invention is a method for reducing the level of HIV titers in a mammal by administering to the mammal a peptide composition of the present invention in an amount effective to reduce the level of HIV titers. The peptide conjugate compositions of the present invention induce prolonged antibody response in serum, a high level of antibody in the mucosa, and the production of cytotoxic lymphocytes. The peptide conjugate compositions of the present invention also elicit neutralizing antibodies and decrease viral loads in a subject.

    摘要翻译： 本发明提供了肽缀合物组合物，使用肽缀合物组合物的方法和包含肽缀合物组合物的药物组合物。 肽缀合物组合物包含具有类似于HIV的gp120主要中和结构域（PND），HIV，gp41和Nef（p27）以及增强免疫原性的载体的氨基酸序列的肽。 本发明的肽缀合物组合物可以包含若干不同肽缀合物的多价混合物。 本发明还提供了通过向哺乳动物施用有效降低HIV滴度水平的量的本发明的肽组合物来降低哺乳动物的HIV滴度水平的方法。 本发明的肽缀合物组合物诱导血清中延长的抗体应答，粘膜中的高水平抗体和细胞毒性淋巴细胞的产生。 本发明的肽缀合物组合物还引发中和抗体并降低受试者的病毒载量。

    Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
    10.
    发明授权
    Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients 失效
    抗髓磷脂碱性蛋白的肽特异性和髓鞘碱性蛋白质肽对多发性硬化患者的施用

    公开(公告)号：US06252040B1

    公开(公告)日：2001-06-26

    申请号：US09055263

    申请日：1998-04-06

    申请人： Kenneth G. Warren ,  Ingrid Catz

    发明人： Kenneth G. Warren ,  Ingrid Catz

    IPC分类号： A61K3804

    CPC分类号： C07K14/4713 ,  A61K38/00

    摘要： Human myelin basic protein (h-MBP) has a molecular weight of 18.5 KD and contains 170 amino acid residues. Synthetic peptides ranging in length from about 8 to 25 residues and covering the entire length of the protein have been produced. Antibodies to h-MBP (anti-MBP) were found to be neutralized by the synthetic peptides, in vitro, which span the h-MBP from about amino acid residue 61 to about amino acid residue 106. The peptides, which cover both the amino (about residues 1 to 63) and carboxy (about residues 117 to 162) terminals of h-MBP did not neutralize purified anti-MBP. Intrathecal administratin of peptide MBP(75-95), MBP(86-95), or MBP(82-98) produced complete binding-neutralization of free (F) anti-MBP with no change in bound (B) levels. A control peptide MBP35-58 had no effect on F or B anti-MBP levels. Intravenous administration of MBP(75-95), MBP(86-95), or MBP(82-98) resulted in significant decline of F and B CSF anti-MBP levels. Administration of MBP synthetic peptides to MS patients either intrathecally or intravenously did not have any adverse neurological effects and systemic complications did not occur. The MBP epitope for MS anti-MBP has been localized to an area between amino acid 86 and amino acid 95.

    摘要翻译： 人髓磷脂碱性蛋白（h-MBP）的分子量为18.5KD，含有170个氨基酸残基。 已经生产了长度为约8至25个残基并覆盖蛋白质整个长度的合成肽。 发现h-MBP（抗MBP）的抗体在体外被合成肽中和，其跨越从约氨基酸残基61至约氨基酸残基106的h-MBP。涵盖氨基酸 （约1至63个残基）和羧基（约117至162个）末端未中和纯化的抗MBP。 肽MBP（75-95），MBP（86-95）或MBP（82-98）的鞘内给药产生游离（F）抗MBP的完全结合中和，结合（B）水平没有变化。 对照肽MBP35-58对F或B抗MBP水平没有影响。 MBP（75-95），MBP（86-95）或MBP（82-98）的静脉内给药导致F和B CSF抗MBP水平显着下降。 对鞘内或静脉内的MS患者施用MBP合成肽没有任何不良神经系统的影响，并没有发生全身并发症。 MS抗MBP的MBP表位已经定位于氨基酸86和氨基酸95之间的区域。